Conditions: Head and Neck Cancer
Keywords: squamous cell cancer of head and neck SCCHN
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 4
Healthy volunteers: no

Brief summary:
Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Erlotinib
Intervention descriptions: intervention 1: 150 mg per day orally until disease progression occurs, up to a maximum of 12 months

Protocol document: